Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source

ClinicalTrials.gov

Source record ID

NCT00118352

Title field or adapter rule

protocolSection.identificationModule.officialTitle

Ingested At

2026-04-28T10:36:33.643216+00:00

Published At

2017-05-30T00:00:00+00:00

Record Updated At

2017-05-30

Results Posted At

2017-05-30

Timestamp Basis

source retrieval time was not retained by the feed adapter

Date limitation

source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions

["Acute Undifferentiated Leukemia", "Adult Acute Lymphoblastic Leukemia in Remission", "Adult Acute Myeloid Leukemia in Remission", "Adult Nasal Type Extranodal NK/T-cell Lymphoma", "Anaplastic Large Cell Lymphoma", "Angioimmunoblastic T-cell Lymphoma", "Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative", "Childhood Acute Lymphoblastic Leukemia in Remission", "Childhood Acute Myeloid Leukemia in Remission", "Childhood Burkitt Lymphoma", "Childhood Chronic Myelogenous Leukemia", "Childhood Diffuse Large Cell Lymphoma", "Childhood Immunoblastic Large Cell Lymphoma", "Childhood Myelodysplastic Syndromes", "Childhood Nasal Type Extranodal NK/T-cell Lymphoma", "Chronic Myelomonocytic Leukemia", "Chronic Phase Chronic Myelogenous Leukemia", "Cutaneous B-cell Non-Hodgkin Lymphoma", "Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue", "Hepatosplenic T-cell Lymphoma", "Intraocular Lymphoma", "Juvenile Myelomonocytic Leukemia", "Mast Cell Leukemia", "Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable", "Nodal Marginal Zone B-cell Lymphoma", "Noncutaneous Extranodal Lymphoma", "Peripheral T-cell Lymphoma", "Previously Treated Myelodysplastic Syndromes", "Recurrent Adult Acute Lymphoblastic Leukemia", "Recurrent Adult Acute Myeloid Leukemia", "Recurrent Adult Burkitt Lymphoma", "Recurrent Adult Diffuse Large Cell Lymphoma", "Recurrent Adult Diffuse Mixed Cell Lymphoma", "Recurrent Adult Diffuse Small Cleaved Cell Lymphoma", "Recurrent Adult Grade III Lymphomatoid Granulomatosis", "Recurrent Adult Hodgkin Lymphoma", "Recurrent Adult Immunoblastic Large Cell Lymphoma", "Recurrent Adult Lymphoblastic Lymphoma", "Recurrent Adult T-cell Leukemia/Lymphoma", "Recurrent Childhood Acute Lymphoblastic Leukemia", "Recurrent Childhood Acute Myeloid Leukemia", "Recurrent Childhood Anaplastic Large Cell Lymphoma", "Recurrent Childhood Grade III Lymphomatoid Granulomatosis", "Recurrent Childhood Large Cell Lymphoma", "Recurrent Childhood Lymphoblastic Lymphoma", "Recurrent Childhood Small Noncleaved Cell Lymphoma", "Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma", "Recurrent Grade 1 Follicular Lymphoma", "Recurrent Grade 2 Follicular Lymphoma", "Recurrent Grade 3 Follicular Lymphoma", "Recurrent Mantle Cell Lymphoma", "Recurrent Marginal Zone Lymphoma", "Recurrent Mycosis Fungoides/Sezary Syndrome", "Recurrent Small Lymphocytic Lymphoma", "Recurrent/Refractory Childhood Hodgkin Lymphoma", "Refractory Chronic Lymphocytic Leukemia", "Refractory Hairy Cell Leukemia", "Refractory Multiple Myeloma", "Relapsing Chronic Myelogenous Leukemia", "Secondary Myelodysplastic Syndromes", "Small Intestine Lymphoma", "Splenic Marginal Zone Lymphoma", "Testicular Lymphoma", "Waldenstr\u00f6m Macroglobulinemia"]

protocolSection.statusModule.lastUpdatePostDateStruct.date

"2017-05-30"

protocolSection.identificationModule.nctId

"NCT00118352"

protocolSection.identificationModule.officialTitle

"Campath (Alemtuzumab) Dose Escalation, Low-Dose TBI and Fludarabine Followed by HLA Class II Mismatched Donor Stem Cell Transplantation for Patients With Hematologic Malignancies: A Multicenter Trial"

protocolSection.statusModule.overallStatus

"COMPLETED"

protocolSection.designModule.phases

["PHASE2"]

protocolSection.statusModule.resultsFirstPostDateStruct.date

"2017-05-30"

Study condition terms

• Acute Undifferentiated Leukemia (protocolSection.conditionsModule.conditions)
• Adult Acute Lymphoblastic Leukemia in Remission (protocolSection.conditionsModule.conditions)
• Adult Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
• Adult Nasal Type Extranodal NK/T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Angioimmunoblastic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative (protocolSection.conditionsModule.conditions)
• Childhood Acute Lymphoblastic Leukemia in Remission (protocolSection.conditionsModule.conditions)
• Childhood Acute Myeloid Leukemia in Remission (protocolSection.conditionsModule.conditions)
• Childhood Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Childhood Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Childhood Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Childhood Immunoblastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Childhood Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
• Childhood Nasal Type Extranodal NK/T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
• Chronic Phase Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Cutaneous B-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue (protocolSection.conditionsModule.conditions)
• Hepatosplenic T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Intraocular Lymphoma (protocolSection.conditionsModule.conditions)
• Juvenile Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
• Mast Cell Leukemia (protocolSection.conditionsModule.conditions)
• Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable (protocolSection.conditionsModule.conditions)
• Nodal Marginal Zone B-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Noncutaneous Extranodal Lymphoma (protocolSection.conditionsModule.conditions)
• Peripheral T-cell Lymphoma (protocolSection.conditionsModule.conditions)
• Previously Treated Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
• Recurrent Adult Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Adult Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Adult Burkitt Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Diffuse Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Diffuse Mixed Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Diffuse Small Cleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Grade III Lymphomatoid Granulomatosis (protocolSection.conditionsModule.conditions)
• Recurrent Adult Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Immunoblastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Adult T-cell Leukemia/Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Anaplastic Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Grade III Lymphomatoid Granulomatosis (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Large Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Lymphoblastic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Childhood Small Noncleaved Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 1 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 2 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Grade 3 Follicular Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Mantle Cell Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent Mycosis Fungoides/Sezary Syndrome (protocolSection.conditionsModule.conditions)
• Recurrent Small Lymphocytic Lymphoma (protocolSection.conditionsModule.conditions)
• Recurrent/Refractory Childhood Hodgkin Lymphoma (protocolSection.conditionsModule.conditions)
• Refractory Chronic Lymphocytic Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Hairy Cell Leukemia (protocolSection.conditionsModule.conditions)
• Refractory Multiple Myeloma (protocolSection.conditionsModule.conditions)
• Relapsing Chronic Myelogenous Leukemia (protocolSection.conditionsModule.conditions)
• Secondary Myelodysplastic Syndromes (protocolSection.conditionsModule.conditions)
• Small Intestine Lymphoma (protocolSection.conditionsModule.conditions)
• Splenic Marginal Zone Lymphoma (protocolSection.conditionsModule.conditions)
• Testicular Lymphoma (protocolSection.conditionsModule.conditions)
• Waldenström Macroglobulinemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.